Gilead Sciences has announced commitments totaling more than $22 million in support of grantees and communities impacted by COVID-19.
The commitments include $20 million to the Gilead CARES (COVID-19 Acute Relief and Emergency Support) Grantee Fund, which will provide support to current grantees facing imminent closure or the termination of critical services due to coronavirus-related losses. Eligible grantees may apply for grants of up to $100,000.
The company also will contribute $1 million to the San Mateo County Strong Fund, which is providing financial assistance to individuals, small businesses, and nonprofits in San Mateo County, where the company is based, and $1 million to the Mayor's Fund for Los Angeles, which is providing support for families and small businesses, relief for healthcare workers, and other services in the Los Angeles area, where Kite, a Gilead operating company focused on cell therapy, is headquartered.
In addition, the company will match employee donations to three global relief organizations working to address the pandemic: Direct Relief, the United Nations Foundation's COVID-19 Solidarity Response Fund, and International Medical Corps.
"Around the world, we are hearing from nonprofit organizations that they are struggling to meet the needs of the communities they serve during the COVID-19 crisis," said Brett Pletcher, Gilead's general counsel and executive vice president for corporate affairs. "For many years, we have stood with community-based organizations that provide critical support to people living with HIV, viral hepatitis, cancer, and other illnesses. It is in recognition of the importance of their work that we are launching this fund to help these groups remain financially sustainable for the long term."
(Photo credit: Gilead Sciences)